Fact-checked by Grok 2 weeks ago

Novozymes

Novozymes A/S was a Danish multinational biotechnology company headquartered in Bagsværd, near Copenhagen, that specialized in the research, development, production, and sale of industrial enzymes, microorganisms, and related biosolutions for applications across multiple sectors, including household care, food and beverages, agriculture, biofuels, and pharmaceuticals.^[1] Founded in 2000 as a spin-out from the pharmaceutical giant Novo Nordisk, its origins traced back to 1925 through the establishment of Novo Terapeutisk Laboratorium by brothers Harald and Thorvald Pedersen, which initially focused on insulin production before expanding into enzyme technologies.^[2] In January 2024, Novozymes completed a merger with Chr. Hansen Holding A/S—approved by regulatory bodies including the European Commission—to form Novonesis, creating a combined entity with approximately 10,000 employees, annual revenues exceeding €3.7 billion, and a strengthened position as a global leader in sustainable biosolutions. As of 2025, Novonesis reported 8% organic sales growth in the first nine months, building on the merged entity's foundation.^[3]^[4]^[5] The company's enzyme and microbial technologies were pivotal in advancing industrial sustainability, enabling processes that reduced reliance on fossil fuels, chemicals, water, and energy while improving efficiency in areas such as detergent formulations for stain removal at lower temperatures, biofuel production from biomass, and food processing for higher yields and reduced waste.^[6] Novozymes operated in over 40 industry sectors and more than 130 markets worldwide, with production facilities in Denmark, the United States, China, and other locations, and it invested heavily in R&D—spending approximately 13% of revenues annually—to discover and engineer novel biocatalysts through protein engineering and microbial screening.^[2]^[7] By the time of the merger, Novozymes had achieved significant environmental impact, including contributions to global CO2 reductions equivalent to removing millions of cars from roads annually through its bioenergy and household care solutions.^[8] Key milestones in Novozymes' independent history included the inauguration of its first dedicated enzyme production plant in Kalundborg, Denmark, in 1969, which marked the shift toward industrial-scale biotechnology, and subsequent expansions through acquisitions like Delta Biotechnology in 2006 for biopharmaceuticals and partnerships for crop protection solutions.^[9] The merger with Chr. Hansen not only consolidated expertise in enzymes with probiotics, cultures, and natural colors but also aligned with Novozymes' long-standing commitment to biology-driven innovation for planetary health, setting the stage for accelerated progress toward UN Sustainable Development Goals.^[10]

Overview

Founding and Origins

Novozymes' roots lie in the establishment of Novo Terapeutisk Laboratorium in 1925 by brothers Harald and Thorvald Pedersen in Copenhagen, Denmark. The Pedersen brothers, previously employed at the rival Nordisk Insulinlaboratorium, founded the company to produce insulin, a groundbreaking treatment for diabetes recently discovered in 1921. Initially operating from a modest facility on Fuglebakkevej, Novo Terapeutisk Laboratorium quickly advanced insulin production techniques, including the development of a stable liquid form marketed as Insulin Novo, which helped establish the company as a key player in pharmaceutical biotechnology.^[11]^[9] From 1925 to 2000, Novo Terapeutisk Laboratorium evolved within the broader Novo Nordisk organization, expanding beyond pharmaceuticals into industrial applications. In 1979, Novo established an environmental department to tackle production-related challenges, such as studying and mitigating obnoxious odors in manufacturing processes, reflecting early commitments to sustainable biotechnology practices. This period also saw significant growth, including Novo's listing on the New York Stock Exchange in 1981 as the first Scandinavian company to achieve this milestone, which facilitated international expansion and investment in enzyme research. By the late 1990s, following the 1989 merger of Novo and Nordisk to form Novo Nordisk A/S, the company's enzyme division had become a distinct and innovative segment, specializing in microbial fermentation for industrial uses like detergents and textiles.^[9]^[12] The formal creation of Novozymes as an independent entity occurred in 2000 through a demerger from Novo Nordisk A/S, approved at an extraordinary general meeting and completed in November of that year. Headquartered in Bagsværd, Denmark, Novozymes A/S was established to concentrate solely on industrial enzymes and microorganisms, separating this business from Novo Nordisk's core pharmaceutical focus on diabetes and other therapeutics. This spin-off leveraged decades of accumulated expertise in biotechnology, positioning Novozymes as a dedicated leader in sustainable industrial solutions from its inception.^[11]^[13]

Core Business Focus

Novozymes specialized in the research, development, production, and sale of industrial enzymes, microorganisms, and biopharmaceutical ingredients, positioning itself as a key player in biotechnology innovation.^[14]^[15] This focus enabled the company to deliver biological solutions that enhanced efficiency across multiple sectors, drawing on advanced protein engineering and microbial technologies to create tailored biotech products.^[16] As the world's leading producer of industrial enzymes, Novozymes held a dominant market position, offering over 500 products by the early 2000s to support diverse industrial needs.^[16]^[15] The company's extensive portfolio underscored its scale and expertise, with production facilities optimized for high-volume manufacturing of these bio-based components.^[17] Central to Novozymes' business strategy was the development of biosolutions that promoted sustainability, such as enzyme-based alternatives to traditional chemical processes that reduced environmental impact and resource consumption.^[18] These innovations facilitated bio-based substitutions in manufacturing, helping industries transition toward more eco-friendly practices while maintaining performance standards.^[19] This focus continued until the company's merger with Chr. Hansen in January 2024 to form Novonesis.^[3]

History

Pre-Spin-Off Era

Novo Terapeutisk Laboratorium was founded in 1925 by brothers Harald and Thorvald Pedersen in Copenhagen, Denmark, initially focused on producing insulin from animal pancreases to address diabetes treatment needs.^[11] As the company extracted insulin, it discovered residual enzymes in the pancreatic glands, prompting early exploration into enzyme research alongside its pharmaceutical core.^[2] By the 1940s, amid World War II shortages, Novo began producing trypsin from gland residues for industrial uses like leather tanning, marking its initial foray into non-pharmaceutical enzyme applications.^[20] This period saw the company shift toward microbial fermentation techniques in the 1950s to produce enzymes such as amylases for textile desizing, reducing dependence on animal sources and enabling scalable production through bacterial and fungal cultures.^[2] In 1963, Novo launched Alcalase, the first microbial fermentation-based detergent enzyme, which facilitated protein stain removal in laundry and expanded microbial applications into household products.^[20] The 1970s brought challenges when a U.S. health campaign alleged respiratory risks from enzyme dust in detergents, causing a temporary sales drop, though recovery followed after safety validations.^[20] In 1979, Novo established an enzyme production facility in North Carolina to manufacture enzymes for high-fructose corn syrup, enhancing industrial capabilities and supporting sustainable processing in food production.^[20] Following the 1989 merger of Novo Industri and Nordisk Gentofte to form Novo Nordisk A/S, the company accelerated its industrial enzyme expansion, achieving approximately 50% global market share in detergent enzymes by the early 1990s through innovations like the 1987 introduction of Lipolase, the first genetically engineered lipase for fat stain degradation.^[11]^[21] Novo Nordisk's 1981 listing on the New York Stock Exchange, as the first Scandinavian firm to do so, provided capital for further enzyme R&D and global facility investments, including a $100 million expansion in North Carolina in 1992. By the late 1990s, Novo Nordisk recognized diverging strategic priorities between its pharmaceutical insulin business and growing industrial biotechnology operations, leading to a 1999 announcement to separate the enzyme division to allow focused growth in each sector.^[22] This decision culminated in preparations for the 2000 demerger, positioning the enzyme business—rooted in decades of microbial innovation—for independent development while Novo Nordisk concentrated on human health therapeutics.^[11]

Spin-Off and Initial Growth (2000-2010)

Novozymes was officially spun off from Novo Nordisk on November 16, 2000, becoming an independent publicly listed company focused on industrial enzymes and microorganisms, with an initial workforce of more than 3,000 employees worldwide.^[16] The spin-off allowed Novozymes to concentrate on its core strengths in biotechnology, particularly enzymes for detergents, which accounted for a significant portion of its early revenue, and emerging applications in biofuels to support sustainable energy production. In its inaugural full year of operations, the company reported sales of DKK 5,271 million, establishing a strong foundation in global markets while leveraging its estimated 40% share of the industrial enzyme sector.^[23]^[24] During the mid-2000s, Novozymes pursued strategic acquisitions to diversify beyond traditional enzymes into biopharmaceutical ingredients. In 2006, it acquired Australian biotechnology firm GroPep Limited for approximately DKK 394 million, enhancing its capabilities in recombinant protein production for biopharma applications such as cell culture media and growth factors.^[25] Later that year, Novozymes completed the purchase of Delta Biotechnology Ltd from the sanofi-aventis group for an undisclosed amount, integrating Delta's expertise in particle-based drug delivery and albumin technologies to further bolster its biopharmaceutical portfolio.^[26] These moves positioned Novozymes as a growing player in high-value biotech segments, complementing its industrial enzyme leadership. By 2008, Novozymes marked significant operational milestones amid rapid expansion in Asia. The company inaugurated the expanded Hongda production facility in Taicang, China, investing over 600 million yuan (about DKK 500 million) to create the world's largest enzyme fermentation plant, primarily supporting bioethanol enzyme production to meet rising demand in biofuels.^[27] This facility underscored Novozymes' commitment to scaling manufacturing for sustainable applications. That same year, the company surpassed the milestone of offering more than 500 enzyme and microbial products across diverse industries, reflecting its innovation-driven growth.^[9] Over the decade, these developments drove revenue to DKK 10 billion by 2010, doubling from the spin-off era and solidifying Novozymes' market positioning as a biotech leader.^[28]

Expansion and Key Milestones (2010-2023)

During the period from 2011 to 2015, Novozymes intensified its investments in biofuel enzyme technologies to support the global shift toward renewable energy sources. In 2012, the company opened a $200 million enzyme production facility in Blair, Nebraska, dedicated to supplying enzymes for converting biomass into biofuels, enhancing production capacity for both U.S. and international ethanol plants.^[29] Additionally, in 2012, Novozymes acquired a 10% stake in Beta Renewables for $115 million, enabling joint commercialization and demonstration of cellulosic biofuel solutions using advanced enzyme technologies.^[30] These initiatives aligned with broader sustainability goals, including a 2011 target to enable a 45 million ton reduction in CO2 emissions through enzyme-enabled processes across industries.^[31] A notable innovation in this era was the 2015 development of a depolymerase enzyme for recycling polyethylene terephthalate (PET) plastics, patented as a method to break down mixed PET articles into monomers for reuse, advancing circular economy efforts in waste management. From 2016 to 2020, Novozymes expanded its footprint in agriculture through the BioAg division, which focused on microbial and enzyme-based solutions for crop enhancement and sustainability. Building on the 2014 BioAg Alliance with Monsanto (later Bayer), the division launched key products such as a jointly developed microbial seed coating in 2016, aimed at improving crop yields and nutrient uptake on over 90 million acres by 2025.^[32] This partnership combined Novozymes' enzyme expertise with microbial discovery, contributing 14% to total sales by 2019 and positioning BioAg as a growth driver in sustainable farming practices.^[33] In 2021, Novozymes outlined an ambitious growth strategy, targeting a doubling of company revenue by 2030 through an organic sales compound annual growth rate (CAGR) of over 5%, supported by investments in biotechnology innovation and market expansion.^[34] This plan emphasized accelerating solutions for climate neutrality and food system transformation while maintaining strong profitability. A pivotal milestone came in 2022 with the announcement of a statutory merger with Chr. Hansen, forming a global biosolutions leader with combined annual revenue of approximately €3.5 billion and expected synergies of €200 million.^[35] The merger, completed in early 2024, built on Novozymes' scaling efforts. Key milestones during this expansion phase included steady workforce growth, reaching 6,756 employees by the end of 2023, reflecting increased global operations.^[36] Novozymes also strengthened its presence in Asia-Pacific markets, where sales accounted for 19% of total revenue by 2013 and achieved 10% organic growth in 2022, driven by new facilities and partnerships in China to support regional biofuel and industrial enzyme demand.^[7]

Merger with Chr. Hansen

In December 2022, Novozymes and Chr. Hansen announced an all-stock merger agreement valued at approximately DKK 85 billion (about $12.3 billion), under which Chr. Hansen shareholders would receive 1.5326 Novozymes B shares per Chr. Hansen share, representing a 49% premium to Chr. Hansen's undisturbed share price.^[35] The transaction, structured as a statutory merger under Danish law with Chr. Hansen dissolving into Novozymes as the surviving entity, aimed to create a global leader in biosolutions by combining complementary strengths in enzymes, microbes, and cultures.^[35] Throughout 2023, the merger progressed with key regulatory and preparatory milestones, including shareholder approvals in March and the selection of "Novonesis" as the future company name in December, derived from Latin roots meaning "a new beginning" to symbolize innovation in biosolutions.^[4] On December 12, 2023, the European Commission granted unconditional approval under the EU Merger Regulation, clearing the path after addressing competition concerns in bioscience markets.^[37] The merger completed on January 29, 2024, following final registration with the Danish Business Authority, forming Novonesis with approximately 10,000 employees worldwide and combined annual revenue of about €3.7 billion.^[38] Novozymes transitioned to a legacy brand within the new entity, which reorganized into three divisions—Food & Beverages, Human Health & Nutrition, and Plant, Animal Health & Tech—to leverage synergies across biosolutions.^[38] The merger's rationale centered on creating scale and innovation to tackle global challenges in sustainable food production, human health, and environmental protection, with the combined portfolio enabling broader applications in reducing chemical use and advancing climate-neutral solutions.^[35] Expected synergies included €200 million in annual revenue growth and €80-90 million in cost savings, primarily from procurement, supply chain, and administrative efficiencies; full cost synergies were achieved by mid-2025, as confirmed in the company's H1 2025 interim report.^[35]^[39]

Products and Technologies

Enzyme and Microorganism Portfolio

Novozymes maintained an extensive portfolio of industrial enzymes, primarily categorized into hydrolases such as proteases, lipases, and amylases, which facilitated various biochemical processes in manufacturing and consumer products.^[40] Proteases, including variants of subtilisin derived from Bacillus species, broke down protein-based substrates and were engineered for stability in harsh conditions like high pH and temperature.^[41] Lipases hydrolyzed fats and oils, enabling efficient lipid processing in applications ranging from food production to waste degradation.^[42] Amylases, such as alpha-amylases, catalyzed the breakdown of starches into sugars, supporting conversions in biofuel and food industries.^[43] These enzyme classes represented core offerings, with ongoing protein engineering to enhance performance and specificity.^[2] In the biofuel sector, Novozymes' enzyme lines included specialized glucoamylases and cellulases for ethanol production, such as the Spirizyme® series that improved starch-to-ethanol conversion yields by targeting residual sugars like trehalose.^[44] Products like Liquozyme® LpH operated effectively at low pH levels, reducing chemical inputs and operational costs in ethanol plants.^[45] For detergents, subtilisin-based proteases like those in the Savinase® family provided robust stain removal on proteinaceous soils, while complementary lipases and amylases addressed lipid and starch stains, respectively.^[46] Novozymes' microorganism solutions, particularly through its BioAg division, encompassed microbial inoculants and biocontrol agents designed to enhance agricultural productivity. Bioyield products like TagTeam® LCO integrated nitrogen-fixing bacteria such as Bradyrhizobium japonicum with phosphate-solubilizing Penicillium bilaiae, promoting symbiotic nitrogen fixation in legumes and improving nutrient uptake for increased yields.^[47] These microbes formed root nodules to convert atmospheric nitrogen into plant-usable forms, with field trials showing yield gains of up to 276 lbs/acre in peanuts.^[47] For plant health, biostimulants such as JumpStart® utilized Penicillium bilaiae to solubilize bound soil phosphorus, enhancing early crop vigor and stress tolerance in cool conditions.^[47] Biocontrol agents in the portfolio featured beneficial bacteria and fungi, such as Bacillus amyloliquefaciens and Trichoderma virens in BioniQ®, to suppress soil-borne pests and diseases through competitive exclusion and antimicrobial production.^[47] These solutions reduced reliance on chemical pesticides while boosting nutrient efficiency, with demonstrated wheat yield improvements of 3.8 bushels/acre.^[47] In waste management, microbial blends targeted organic degradation in wastewater treatment, with diverse consortia breaking down fats, oils, and greases to enhance plant performance and sludge dewaterability via products like BioSec®.^[48] Following the 2024 merger with Chr. Hansen to form Novonesis, this enzyme and microorganism portfolio was integrated into the new entity's biosolutions offerings.^[38]

Biopharmaceutical Ingredients

Novozymes was a key provider of recombinant proteins for biopharmaceutical applications, particularly in drug formulation and stabilization. The company's flagship product in this area was Recombumin®, the world's first commercially available, animal-free recombinant human albumin (rHA) produced using yeast expression technology. This multifunctional excipient was utilized to stabilize therapeutic proteins, enhance drug delivery for both proteins and small molecules, and serve as a component in cell culture media, offering a safer alternative to animal-derived albumins by eliminating risks of viral contamination and immunogenicity issues.^[49] Recombumin® variants, such as Recombumin Alpha and Prime, maintained the same core molecule while providing options for different formulation needs, ensuring regulatory compliance for human therapeutics.^[50] Other recombinant proteins in Novozymes' portfolio included DeltaFerrin™, a transferrin alternative for iron transport in cell culture, further supporting biopharma manufacturing processes.^[51] In 2006, Novozymes acquired Australian biotechnology firm GroPep Limited for approximately $65 million, significantly bolstering its capabilities in recombinant growth factors for biopharmaceutical cell culture. GroPep's expertise enabled the production of animal-free growth factors such as Long®R3 IGF-1, a modified insulin-like growth factor used to promote cell proliferation in media for therapeutic protein expression, and fibroblast growth factor (FGF) analogues that enhanced stem cell maintenance and differentiation in bioprocessing. This acquisition integrated GroPep's recombinant protein technologies into Novozymes' platform, expanding the range of high-purity, GMP-compliant supplements for optimizing yields in mammalian cell cultures used for biologics production.^[52]^[53] Novozymes' biopharmaceutical ingredients found critical applications in vaccine production, where recombinant human albumin stabilized antigens and supported cell-based manufacturing. For instance, Recombumin® was incorporated into both developmental and marketed vaccines to improve stability during storage and administration, while animal-free supplements like those from GroPep facilitated serum-free viral vaccine production by boosting host cell growth. Additionally, stemming from its origins as a 2000 spin-off from Novo Nordisk—a pioneer in recombinant insulin since the 1980s—Novozymes leveraged shared heritage in protein engineering to supply enzymes and ingredients for insulin analog manufacturing. Through collaborations, such as the 2021 partnership with Novo Nordisk Pharmatech to develop best-in-class technical enzymes, specialized enzymes like TrypsiNNex® were developed for efficient processing in recombinant insulin production, ensuring high-purity analogs for diabetes therapies.^[54]^[55]^[56]^[57] Following the 2024 merger, these biopharmaceutical ingredients continued as part of Novonesis' offerings.^[38]

Applications and Markets

Industrial and Household Uses

Novozymes' enzymes played a pivotal role in household cleaning products, particularly laundry detergents, where they enabled effective stain removal at lower temperatures and with reduced dosages. Proteases, amylases, and lipases broke down protein, starch, and fat-based stains, respectively, enhancing cleaning performance while allowing for cold-water washing cycles that saved energy. These enzymatic solutions were incorporated into formulations from major global brands, contributing to more sustainable consumer products by minimizing the need for harsh chemicals and high-temperature processing.^[58] In the industrial sector, Novozymes supplied cellulase enzymes, such as the Cellic® CTec3 series, for biofuel production, specifically converting lignocellulosic biomass into fermentable sugars for bioethanol manufacturing. This application supported the shift toward renewable energy by improving conversion efficiency and reducing production costs compared to traditional methods. In the textiles industry, amylase-based desizing enzymes removed starch coatings from yarns prior to dyeing and weaving, preserving fabric integrity while cutting water and energy consumption in processing.^[59]^[60] For the pulp and paper sector, Novozymes' xylanase enzymes, like Xylio® Pre, enhanced bleachability by breaking down hemicellulose barriers, allowing for reduced chlorine or other bleaching agents while maintaining pulp brightness and strength. This enzymatic approach minimized environmental discharges and supported the use of recycled fibers. Overall, these applications drove sustainability by replacing chemical-intensive processes; for instance, enzyme integration in textiles and pulp production could reduce chemical usage by 20-30% and lower energy demands, thereby decreasing the ecological footprint of manufacturing operations.^[61]^[62]^[63]

Agriculture and Food Sectors

Novozymes developed BioAg solutions that leveraged microbial inoculants to enhance crop yields and nutrient efficiency in agriculture. These products, such as TagTeam® and JumpStart®, promoted nitrogen fixation and phosphate solubilization, allowing plants to access nutrients more effectively and complementing traditional fertilizers. For instance, TagTeam® LCO for soybeans demonstrated yield increases of up to 1.4 bushels per acre through improved nodulation and nutrient availability in field trials.^[47] Similarly, JumpStart® improved the availability of phosphate from fertilizers, where up to 90% could otherwise go unused in the year of application, fostering root development and overall plant health across various crops like corn and peas.^[47] These biologicals reduced reliance on synthetic inputs while supporting sustainable farming practices.^[64] In the food sector, Novozymes provided enzymes that optimized production processes and improved product quality. For baking, amylases like Fungamyl® broke down starches to generate fermentable sugars, resulting in higher bread volume, improved crumb structure, and extended freshness without altering flavor.^[65] In dairy applications, fermentation-produced chymosin such as Chy-Max® served as a vegetarian rennet alternative, enabling consistent milk coagulation for cheese production while increasing yield and maintaining texture during storage.^[66] For brewing, glucoamylase enzymes like Attenuzyme® Pro hydrolyzed dextrins into glucose, achieving higher attenuation levels for light beers and enhancing fermentation efficiency.^[67] The 2024 merger with Chr. Hansen expanded these offerings by integrating complementary microbial cultures for dairy and baking.^[38] To address post-harvest losses, Novozymes partnered with AgroFresh in 2022 to develop biological antifungals that controlled pathogens on fruits and vegetables, thereby extending shelf life and reducing food waste.^[68] These solutions targeted fungal spoilage, promoting sustainable preservation methods that minimized chemical use in the supply chain.^[69]

Research and Development

R&D Infrastructure

Novozymes dedicated approximately 20% of its global workforce to research and development, with around 1,200 employees focused on R&D activities in 2023.^[70]^[71] The company reinvested approximately 11% of its annual revenue into R&D, totaling DKK 2 billion in 2022 to support ongoing innovation in biosolutions.^[7]^[72] The firm's R&D infrastructure included a global network of approximately 20 research and application centers as of 2022.^[73] In 2022, Novozymes adopted the Benchling R&D Cloud platform across its organization to enable digital tools for sequence design, strain engineering, and collaborative workflows among scientists.^[74] Novozymes secured a DKK 750 million loan from the Nordic Investment Bank in 2022 to finance R&D investments, particularly in enzyme discovery and biotechnology platforms.^[75] This funding underscored the company's emphasis on advanced protein engineering and the integration of AI for predicting protein structures and enhancing innovation efficiency.^[70]

Innovation Pipeline and Achievements

Novozymes achieved several key milestones in enzyme innovation, particularly in advancing sustainable materials processing. In 2019, the company entered a joint development agreement with Carbios to produce proprietary enzymes capable of fully recycling PET plastics and fibers, marking a significant step toward enzymatic biorecycling at scale.^[76] This partnership was strengthened in 2023 with a long-term supply commitment, enabling industrial-scale production of PET-degrading enzymes like PETase and MHETase, which break down plastic waste into reusable monomers.^[77] Earlier efforts in plastic degradation included a 2019 agreement with Carbiolice for embedding degrading enzymes into single-use plastics to promote biodegradation.^[78] In the realm of bio-based materials, Novozymes contributed to the development of bio-based adipic acid in 2021, a key building block for nylon production derived from renewable sources, supporting sustainable polymer manufacturing.^[79] This innovation aligned with broader efforts to replace petroleum-derived chemicals in polyamides, enhancing circularity in textiles and composites.^[80] The company's innovation pipeline emphasized advanced biotechnologies, including gene editing and protein engineering to create custom enzymes tailored for specific industrial challenges. Novozymes leveraged CRISPR-related technologies—recognized through the 2017 Novo Nordisk Foundation Novozymes Prize awarded to key developers—to engineer microbes and enzymes for improved efficiency in sectors like biofuels and agriculture.^[81] Ongoing work focused on optimizing enzyme cocktails via genetic modifications, enabling applications such as enhanced lignocellulosic biomass breakdown and precise degradation of synthetic polymers. By 2023, Novozymes held over 900 active patent families in enzyme and biotechnology domains, reflecting a robust intellectual property portfolio that supported this pipeline.^[82] Novozymes' achievements underscored its role in global sustainability, with biosolutions contributing to multiple United Nations Sustainable Development Goals (SDGs). In 2023, 83% of the company's sales were documented as aligning with at least one of six key SDGs, including Zero Hunger (SDG 2), Good Health and Well-Being (SDG 3), Clean Water and Sanitation (SDG 6), Affordable and Clean Energy (SDG 7), Responsible Consumption and Production (SDG 12), and Climate Action (SDG 13).^[83] These contributions included enzymes that reduced agricultural inputs, enabled low-temperature laundry cycles to save energy, and supported bioenergy production to lower carbon emissions. That same year, Novozymes was recognized by the European Patent Office as Denmark's top innovator with 107 patent filings, the highest among Danish companies, and received the U.S. EPA's Safer Choice Partner of the Year award for advancing safer chemical ingredients.^[84]^[85] Following the 2024 merger with Chr. Hansen to form Novonesis, Novozymes' R&D capabilities were integrated into the new entity's expanded infrastructure.^[70]

Operations and Global Presence

Manufacturing Facilities

Novozymes' manufacturing operations relied on advanced fermentation technologies to produce enzymes and microorganisms at scale, with a primary focus on submerged and solid-state fermentation processes tailored for industrial biotechnology. The company's headquarters in Bagsværd, Denmark, included dedicated fermentation plants that served as the core of its production infrastructure, enabling efficient large-volume synthesis of biological products. These facilities supported the development and scaling of enzyme portfolios for diverse applications, utilizing controlled bioreactors to optimize yield and purity.^[2]^[86] A landmark expansion occurred in 2008 with the inauguration of the Hongda production facility in Taicang, China, which became the world's largest enzyme fermentation plant at the time and significantly enhanced Novozymes' capacity to serve the Asia-Pacific region. In the United States, key sites included the enzyme production facility in Franklinton, North Carolina—established in 1979 as the North American headquarters—and the plant in Salem, Virginia. The Salem facility underwent a $5 million expansion in 2025 to increase capacity and address rising global demand for biosolutions.^[87]^[9]^[88]^[89] Prior to its 2024 merger with Chr. Hansen, Novozymes maintained a global network of production facilities, emphasizing scalable fermentation to meet production demands while minimizing resource intensity. Sustainability was integrated into these operations through biodegradable processes and energy-efficient designs; for example, reverse osmosis optimizations at Danish facilities reduced energy use by thousands of MWh annually, contributing to broader goals of 93% renewable electricity sourcing in 2024 and substantial cuts in operational emissions. Post-merger expansions under Novonesis further optimized these sites for circular biomass management and waste reduction.^[4]^[70]

International Expansion

Novozymes established a robust global footprint, operating in over 30 countries with a strong emphasis on key regions including Europe—headquartered in Bagsværd, Denmark—North America through facilities in the United States and Canada, Asia-Pacific via production sites in China and India, and Latin America with operations in Brazil and Argentina.^[82]^[90] This network supported sales and distribution while enabling proximity to major markets for enzymes and microbial solutions. Key milestones in Novozymes' international growth occurred during the 2000s and 2010s. The company entered the Indian market in 2007 through the acquisition of Biocon's enzyme business for $115 million, enhancing its capabilities in industrial and agricultural enzymes.^[91] In China, expansion accelerated in the early 2000s following an initial presence established in 1997, including the development of local R&D and production facilities to serve the growing bioeconomy.^[92] The 2010s saw a focused push into Brazil's BioAg sector, highlighted by the 2010 acquisition of Turfal, a supplier of microbial inputs for sustainable agriculture, which provided direct access to Latin America's agricultural market and supported a 15% annual growth in related sales.^[93] Prior to its 2024 merger, Novozymes employed approximately 6,800 people across 35 locations worldwide.^[82]^[94] To optimize its global operations, Novozymes adopted strategies centered on localized production, which minimized logistics costs and improved responsiveness to regional demands. This approach included establishing manufacturing sites in high-growth areas, such as enzyme production facilities in China and India for Asia-Pacific markets, and BioAg-focused operations in Brazil. In 2023, this regional strategy contributed to a revenue distribution of approximately 35% from Europe, Middle East & Africa (EMEA), 34% from North America, 19% from Asia-Pacific, and 13% from Latin America.^[82]

Ownership and Financials

Ownership Structure

Novozymes was established as a separate publicly traded company through a spin-off from Novo Nordisk A/S in November 2000, listing its B shares on Nasdaq Copenhagen under the ticker NOVO B. As part of the demerger, Novo A/S, the investment arm of the Novo Nordisk Foundation, retained an initial stake of 25.1% in Novozymes' share capital, providing continued linkage to its pharmaceutical origins while allowing independent operation. Following the initial listing, Novozymes' ownership structure evolved with institutional investors emerging as the primary holders of the freely traded B shares, which carry standard voting rights. By the 2010s, these investors, including major funds like Vanguard Group and Norges Bank Investment Management, collectively dominated the shareholder base, reflecting the company's broad market appeal and growth in the biosolutions sector. The Novo Nordisk Foundation's stake, managed through Novo Holdings A/S, remained stable at approximately 25% of the share capital but represented a minority position amid this institutional predominance. In January 2024, Novozymes merged with Chr. Hansen Holding A/S to form Novonesis A/S, a global biosolutions leader, with the transaction structured as Novozymes issuing new B shares to Chr. Hansen shareholders. This resulted in original Novozymes shareholders retaining approximately 66% ownership in the combined entity, ensuring continuity of control for the pre-merger base. Novonesis maintains a dual-class share structure, with class A shares (held predominantly by Novo Holdings A/S) conferring 1,000 votes each compared to one vote per class B share, thereby securing enhanced voting influence for the foundation-linked entity at 63.4% of total votes despite its 25.5% economic stake.^[38]^[96]

Financial Performance and Metrics

Prior to its merger with Chr. Hansen in early 2024 to form Novonesis, Novozymes achieved revenue of DKK 17.9 billion in 2023, marking a 2% increase from the previous year on a reported basis and 5% organic growth.^[97]^[98] The company's adjusted EBITDA margin stood at approximately 34% for the year, supported by operational efficiencies and pricing strategies amid challenging market conditions.^[99] Novozymes had outlined a strategic target of more than 5% compound annual growth rate (CAGR) in organic sales through 2025, emphasizing investments in high-growth areas such as bioenergy and health biosolutions to drive sustained expansion.^[100] This ambition aligned with the company's long-term trajectory, where revenue expanded from roughly DKK 5 billion in 2000—following its spin-off from Novo Nordisk—to DKK 17.9 billion by 2023, demonstrating consistent scaling through innovation and global market penetration.^[101]^[97] Research and development expenditures represented about 15% of revenue in 2023, totaling DKK 2.7 billion, underscoring Novozymes' commitment to technological leadership in industrial biotechnology.^[102] Following the merger, the legacy Novozymes operations integrated into Novonesis contributed to the combined entity's 8% organic sales growth in the first nine months of 2025, with sales reaching EUR 3.16 billion on a pro forma basis for that period.^[39] Pro forma full-year revenue for 2025 is guided at levels implying continued mid-single-digit growth, building on the prior year's EUR 3.95 billion pro forma sales, while cost synergies from the merger have boosted the adjusted EBITDA margin by 210 basis points by the first half of 2025, reaching 37.4%.^[103]^[104]

References

[1]
Novozymes AS Company Profile - Overview - GlobalData
Novozymes AS (Novozymes) is a biotechnology company, which produces and sells industrial enzymes and microorganisms. The company is headquartered in Bagsvaerd, ...
[2]
The enzyme hunters | Feature - Chemistry World
Feb 26, 2015 · Novozymes traces its history back to 1925, when brothers Harald and Thorvald Pedersen founded Novo Terapeutisk Laboratorium to manufacture ...
[3]
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
Jan 29, 2024 · Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger ... 2024, and the final merger settlement on February 1, 2024.
[4]
Novozymes & Chr. Hansen Announce Future Company Name
Dec 13, 2023 · Novozymes and Chr. Hansen have announced that the name of the future combined company will be 'Novonesis'. Novonesis means 'A new beginning'.
[5]
How Novozymes harnesses the sustainability superpower of enzymes
Oct 23, 2018 · Today, its enzyme-based products and solutions are used in over 40 industry sectors, from household care and bioenergy to agriculture and ...
[6]
[PDF] Novozymes is a $1.6 billion USD global leader in industrial ...
As the world leader in industrial enzymes and microorganisms,. Novozymes has the financial, innovative and organizational strength to continue to improve the ...
[7]
Novozymes - Companies History
Jul 23, 2013 · The first step was a new enzyme plant in Kalundborg, Denmark, inaugurated in 1969. Medical journal The Lancet publishes an article questioning ...
[8]
Novonesis: Chr Hansen and Novozymes merge to form €3.7bn ...
Feb 2, 2024 · The combined group will have an estimated annual revenue of €3.7bn. Coming together to form a 'global biosolutions partner', Novonesis combines ...
[9]
Our heritage | Novo Nordisk | Driving change
Brothers Harald and Thorvald Pedersen, who were former employees of Nordisk, formed their own company, Novo Terapeutisk Laboratorium. Novo and Nordisk competed ...
[10]
[PDF] Form 20-F | Novo Nordisk
Feb 2, 2016 · New York, as the Depositary, have been listed on the New York Stock Exchange since 1981. As of December 31, 2015, 241,037,873 B share ...Missing: 1979 department
[11]
Demerger of Novo Nordisk A/S approved at extraordinary
Nov 13, 2000 · A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place following an ...
[12]
NSISb.CO - | Stock Price & Latest News | Reuters
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ...Missing: core | Show results with:core
[13]
[PDF] Success Story Novozyme - Mettler Toledo
With over 700 products used in 130 countries, Novo- zymes is the world's leading producer of industrial enzymes, microorganisms, and biopharmaceutical.Missing: largest | Show results with:largest
[14]
NOVOZYMES — Driven by research and scientists - Nature
Jan 11, 2001 · Today our industrial enzymes can improve the strengths of nature, so we can reduce waste and replace harmful substances. For 50 years we have ...
[15]
Building the world's most advanced enzyme plant for biofuel - NNE
On 30 May 2012, Novozymes, one of the world's largest enzyme producers, inaugurated a new plant in Blair, Nebraska. The plant produces world-leading enzymes, a ...
[16]
How Novozymes harnesses the sustainability superpower of enzymes
Oct 23, 2018 · For the most part, the company uses fungi (Aspergillus oryzae, mostly) to produce the enzymes that it needs, drawing on the work of its 1,000- ...Missing: core biopharmaceutical ingredients<|control11|><|separator|>
[17]
There's a biosolution for (almost) everything - Novonesis
Enzymatic biosolutions hold the key to reducing the environmental impact of plastics and increasing recyclability. Learn more. Textile. Our biodegradable, ...
[18]
History of Novo Nordisk A/S – FundingUniverse
Novo becomes early producer of crystalline penicillin. 1979: North Carolina enzyme plant is built. 1982: First commercially produced human insulin is marketed.
[19]
Novo-Nordisk Rides the Enzyme Tide - The New York Times
Jan 27, 1991 · Novo-Nordisk produces half the world's industrial enzymes -- those that are mass produced in a factory for commercial use.
[20]
Novo Nordisk to split into two - Pharmaceutical industry news
Feb 24, 1999 · Join industry leaders for a daily roundup of biotech & pharma news. Today's issue. China's API price cuts undermine India's self-sufficiency ...
[21]
[PDF] novozymes - SEC.gov
Mar 11, 2002 · Novozymes was spun off from Novo Nordisk A/S in November 2000. For further company information, visit Novozymes at www.novozymes.com. Stock ...Missing: spin- | Show results with:spin-
[22]
None
Below is a merged summary of the demerger of Novozymes from Novo Nordisk based on the provided segments. To retain all information in a dense and organized manner, I will use a combination of narrative text and a table in CSV format for key details. This ensures clarity and completeness while avoiding redundancy.
[23]
https://www.sec.gov/Archives/edgar/vprr/0201/02015491.pdf
[24]
Novozymes, Inc. Acquires Delta Biotechnology, Ltd.; New company ...
Jul 7, 2006 · Nottingham, UK, 7th July 2006 – Novozymes has acquired Delta Biotechnology Ltd from the sanofi-aventis group. Established in 1984, Delta is, ...
[25]
Novozymes opens largest enzyme facility - All About Feed
Nov 24, 2008 · Novozymes today inaugurates the newest expansion of its Hongda production facility in Taicang, China, making it the largest enzyme ...
[26]
[PDF] THE NOVOZYMES REPORT 2010 - CBCSD
... revenue of DKK 10 billion in 2010. Additionally, the allocation was based on achievement of financial and nonfinancial targets set each year. The exercise ...
[27]
Novozymes opens $200M Neb. enzyme plant
May 31, 2012 · The $200 million project in Blair, Neb., will supply ethanol plants both in the United States and abroad with enzymes for converting sugars and ...
[28]
Novozymes Acquires 10% of Beta Renewables for $115M
Novozymes Acquires 10% of Beta Renewables for $115M; Companies to Jointly Market, Demonstrate and Guarantee Cellulosic Biofuel Solutions. BioChemicals/Renewable ...
[29]
Presentation - Novozymes - YUMPU
Jun 20, 2014 · Short and Long-term Sustainability Targets<br />. Sustainability targets for 2011:<br />. 1. Enable a 45 million ton reduction in CO 2 ...
[30]
Novozymes, Monsanto launches jointly developed seed coating
Dec 5, 2016 · "We believe it could be applied to more than 90 million acres by 2025 and become one of the biggest biological products in the ag industry," ...
[31]
Novozymes gets more partners for bio-agriculture arm beyond Bayer
Apr 5, 2019 · Novozymes' BioAg business is a part of its Agriculture and Feed division, which accounted for 14 percent of its total sales of 14.4 billion ...Missing: launch 2016-2020
[32]
Novozymes is unlocking growth with the ambition of doubling
“We commit to clear 2025-targets while also allowing ourselves to look further ahead with the ambition to double our sales by 2030. The investments we're making ...
[33]
Novozymes and Chr. Hansen to combine and create a leading
Dec 12, 2022 · Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.
[34]
Novozymes: Number of Employees 2011-2025 | NVZMY - Macrotrends
Novozymes total employee count in 2024 was 10,582, a 56.63% increase from 2023. Novozymes total number of employees in 2023 was 6,756, a 0.37% decline from 2022 ...Missing: 3000 2000
[35]
Novozymes delivers historically strong full-year results - Novonesis
Jan 26, 2023 · At Novozymes, we use the power of biotech to create biosolutions to help our customers grow their businesses while enabling a healthier planet.
[36]
Commission clears Novozymes and Chr. Hansen merger
The European Commission has approved, under the EU Merger Regulation, the proposed merger between Novozymes A/S ('Novozymes') and Christian ...
[37]
Combination of Novozymes and Chr. Hansen is completed
Jan 29, 2024 · The combined group will have annual revenue of approximately EUR 3.7 billion1 with solid profitability and cash generation.
[38]
None
### Merger Synergies and Cost Synergies Achievement Status as of 2025
[39]
Bioengineered Enzymes and Precision Fermentation in the Food ...
Jun 15, 2023 · Engineered enzymes such as amylases, xylanases, lipases, proteases, cellulases, and pectinases are utilized in a wide range of food ...
[40]
Subtilisin - an overview | ScienceDirect Topics
Subtilisin is a bacterial protease, with main types being subtilisin Carlsberg and subtilisin BPN, used in detergents.
[41]
[PDF] Novozymes Lipase Products - Strem
Lipases (EC Number 3.1.1.3) are one of the most commonly used classes of enzymes in biocatalysis. They have been used on a variety of substrates and show ...<|separator|>
[42]
Industrial Enzymes - Wiley Online Library
Second-generation detergent proteases, amylases, and lipases were developed by using protein engineering and genetic techniques for further improved ...
[43]
Novozymes launches advanced enzymes to increase ethanol yields ...
Feb 21, 2017 · Novozymes launches advanced enzymes to increase ethanol yields and plant profits. New trehalase products convert sugar that would otherwise be ...
[44]
New Enzyme for Ethanol Producers Reduces Use of Chemicals and ...
(Novozymes) Novozymes Liquozyme® LpH enables smoother ethanol processing at low pH and improves the working environment. -- Today, Novozymes announced the ...
[45]
US8071345B2 - Stabilized subtilisin composition - Google Patents
The present invention relates to a liquid detergent composition comprising a surfactant, a subtilisin and a protease stabilizer that is 3-chlorobenzoic acid ...
[46]
None
### Summary of Novozymes BioAg 2022 Product Guide (US)
[47]
BioSec® | 诺维信
Novozymes has specifically developed these enzymes to condition anaerobically digested sludge and improve dewaterability. BioSec® is used to increase sludge ...<|control11|><|separator|>
[48]
Recombumin® - Bioprocess Online
The world's first and only, animal-free, commercially available recombinant human albumin, approved for use in the manufacture of human therapeutics.
[49]
Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio
Novozymes' rAlbumin products, Albucult and Recombumin, are now under the Recombumin brand as Recombumin Alpha and Recombumin Prime, with the same molecule and ...
[50]
Novozymes Tackles Ingredient Manufacture
Dec 1, 2007 · All of Novozymes cell culture ingredients are animal-free, manufactured under GMP conditions, and capable of supporting optimal cell growth in a ...
[51]
Novozymes will acquire GroPep - C&EN - American Chemical Society
Novozymes has agreed to acquire the Australian biotechnology company GroPep for almost $65 million. GroPep manufactures Long R3 IGF-1, ...
[52]
Novozymes A/S Proposal To Acquire GroPep Limited - BioSpace
Aug 14, 2006 · The acquisition is expected to have very limited impact on Novozymes' financial result for 2006 as the transaction is expected to be completed ...
[53]
Novozymes Biopharma to present latest advances in cell culture ...
Apr 12, 2011 · Study findings highlight the application of animal-free recombinant supplements in cell-based viral vaccine production and animal-free ...
[54]
Novozymes Biopharma Enters Agreement With A Leading Vaccine ...
May 29, 2014 · The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to ...
[55]
Novozymes and Novo Nordisk Pharmatech are joining forces to ...
Nov 25, 2021 · Novozymes and Novo Nordisk Pharmatech are joining forces to develop best-in-class technical enzymes to support production processes in the ...
[56]
Effective production of Recombinant Insulin using TrypsiNNex®
May 30, 2024 · TrypsiNNex is a high-quality recombinant enzyme that addresses critical raw material specifications for biopharmaceutical processing in the recombinant insulin ...
[57]
Grow your household care business with biosolutions
### Summary of Novozymes/Novonesis Enzymes in Household Uses
[58]
Cellic® CTec3 HS - Novonesis
With Novonesis Cellic® CTec3 HS you can cost-efficiently convert lignocellulosic materials to fermentable sugars. It offers process and substrate versatility ...
[59]
Enzymes for desizing - Novonesis
Our starch-degrading enzymes remove the coating without damaging the yarn – giving improved fabric quality, and less chemical and water consumption.
[60]
Enzymes for bleach boosting - Novonesis
Add enzymes before bleaching to enhance the bleachability of brown stock pulp. Add them after bleaching to increase brightness and optical stability in fully ...
[61]
Enzymes and solutions for industrial bioprocessing - Novonesis
Enzymes and biosolutions improve manufacturing, increase sustainability, and help industries like grain, starch, textile, leather, and pulp & paper. They also ...Missing: applications | Show results with:applications
[62]
How Novozymes harnesses the sustainability superpower of enzymes
Oct 25, 2018 · The potential of enzymes to slash energy consumption and reduce chemical use endows these biologically active proteins with something akin to ...
[63]
Bacteria and enzymes for agricultural biosolutions - Novonesis
They work with and enhance natural processes including nitrogen fixation, stress tolerance, and disease protection. ... And our biocontrol solutions provide ...
[64]
Fungamyl® | Novonesis
The result is a good, even bread crumb structure and high bread volume. ... It provides excellent baking performance in various dough-making procedures and bread ...
[65]
Chy-Max® M - Novonesis
Increases cheese yield and offers better process control · Firm texture remains during shelf life · No bitterness · Requires a lower dose · Higher whey quality
[66]
Attenuzyme® Pro - Novonesis
Glucoamylases are typically brewers' first choice when producing highly attenuated beers. Consumers know these as light or low-calorie beers. Combined with ...
[67]
Novozymes and AgroFresh to explore development of biological ...
Jan 10, 2025 · Novozymes and AgroFresh form partnership to unlock the potential of biotechnology to improve post-harvest quality and reduce food waste.
[68]
Novozymes and AgroFresh to explore development of biological ...
Jun 15, 2022 · Novozymes and AgroFresh form partnership to unlock the potential of biotechnology to improve post-harvest quality and reduce food waste.Missing: preservatives | Show results with:preservatives
[69]
[PDF] Annual Report 2024 - Novonesis
Feb 26, 2025 · Novozymes A/S (reg. no.: 10007127). Registered address: Krogshoejvej 36 DK-2880 Bagsvaerd, Denmark, part of Novonesis Group. ambition: People.
[70]
Novozymes - BUSINESS FOR 2030
7.3) By 2030, double the global rate of improvement in energy efficiency. With climate change as a top priority, Novozymes has made considerable investments in ...
[71]
NIB continues to finance Novozymes' R&D investments
NIB and the Danish biotech company Novozymes A/S have agreed on a DKK 750 million (EUR 100 million) loan to finance the company's research and development (R&D ...Missing: 2023 discovery
[72]
[PDF] Novo Nordisk Fonden - Annual Report 2022
Mar 31, 2023 · 2022, Novozymes A/S invested DKK 2 billion in R&D. Novozymes A/S is ranked as number 128 in Europe and 675 globally on R&D invest- ments ...
[73]
Novozymes Is at the Forefront of Digital R&D, Turning Data Into an ...
Nov 17, 2022 · Novozymes, the global leader in biological solutions, will expand the use of the Benchling R&D Cloud across its entire R&D organization.
[74]
NIB continues cooperation with Novozymes - Nordic Investment Bank
Feb 14, 2022 · NIB and the Danish biotech company Novozymes A/S have signed a DKK 750 million (approx. EUR 101 million) loan to finance the company's research ...Missing: 2023 discovery
[75]
Carbios Enters Joint Development Agreement With Novozymes to ...
Jan 30, 2020 · Carbios Enters Joint Development Agreement With Novozymes to Produce Its Proprietary Enzyme for Complete Recycling of PET-plastics and Fibers.
[76]
Carbios and Novozymes strengthen collaboration with long-term ...
Jan 12, 2023 · The partnership ensures enzyme supply for Carbios' recycling tech, long-term production of enzymes, and Novozymes will supply to all licensees.
[77]
Novozymes Signs Deal to Develop Biodegradable Plastics
Jan 31, 2019 · Carbiolice is to embed these enzymes into single-use plastics, such as plastic bags, to help them biodegrade and avoid contributing toxic waste ...
[78]
Recycling technology Novozymes BioBased Adipic Acid ...
Dec 22, 2021 · With this, OMV is taking the next step toward an industrial-scale plant planned for 2026. The patented chemical recycling technology, developed ...
[79]
A sustainable process to 100% bio-based nylons integrated ...
In this study, 100% bio-based nylons were prepared via an integrated chemical and biological process from lignocellulose.
[80]
Novozymes Prize Won by Researchers Behind Tools for Editing the ...
Feb 13, 2017 · "The two Prize winners – Emmanuelle Charpentier and Virginijus Siksnys – have been at the forefront of developing CRISPR technology.Missing: custom enzymes pipeline
[81]
[PDF] The Novozymes - CVR API
Feb 8, 2024 · Most of Novozymes' revenue is derived from the sale of goods to ... DKK 67.7 billion based on a share price of DKK. 361.4. The merger ...
[82]
People. Planet. Positive | Novonesis sustainability ambition
How we enable a healthy planet and healthy lives · Transform food systems · Mitigate climate impact · Protect nature and biodiversity · Enable healthier living.
[83]
Novonesis is recognized as top innovation company in Denmark ...
Mar 27, 2024 · According to the European Patent Office, legacy Novozymes had a total of 107 patent filings in 2023, which is highest among all Danish ...
[84]
2023 Safer Choice Partner of the Year Award Winners | US EPA
Feb 12, 2025 · Novozymes is recognized as an outstanding Safer Choice Innovator. In 2022, Novozymes added six ingredients to CleanGredients, a database of ...Missing: biotech | Show results with:biotech
[85]
Oxygen control for an industrial pilot-scale fed-batch filamentous ...
Current operation. The fermentation at Novozymes Pilot Plant, (Bagsvaerd, Denmark) is carried out in a 2500 L. Filamentous fungal fermentation model. In this ...
[86]
[PDF] The Novozymes Report 2008 - GlobeNewswire
Jan 22, 2009 · expansion of its Hongda production facility in taicang, china, making it the largest enzyme fermentation facility in the world. among other ...
[87]
Global Biotechnology Company Novozymes to Expand in Wake ...
Apr 23, 2014 · Novozymes first opened its doors in North Carolina in 1979 with its North American headquarters and manufacturing plant in Franklinton.
[88]
Novonesis Expands Capacity in Salem, VA, to Meet Global Demand
Apr 22, 2025 · Novonesis, a global leader in biotechnology specializing in enzymes and microbes biosolutions, has announced a $5 million expansion at its Salem, Virginia, ...
[89]
Beat the transformation odds. Novozymes Casestory - ResearchGate
Mar 20, 2024 · . Our core business. Our core business is industrial enzymes, microorganisms, and biopharmaceutical. ingredients. Novozymes employs in-house ...
[90]
Denmark's Novozymes buys India's Biocon enzymes unit - Reuters
Aug 9, 2007 · Denmark's Novozymes <NZYMb.CO> will pay $115 million for the enzymes unit of India's Biocon Ltd. <BION.BO>, strengthening its position in ...Missing: milestone | Show results with:milestone
[91]
The Danish bio-producer that made it in China
Feb 5, 2025 · Novozymes, as it was then known, had a presence in Beijing since the early 1990s. It was only in 1997 that it finally established a Chinese ...
[92]
Novozymes extends reach in sustainable agriculture inputs
Mar 15, 2017 · Novozymes has acquired a Brazilian supplier of microorganism and inputs for sustainable agriculture, in a bid to expand its market position.
[93]
Novozymes inspires pride and direction with internal campaign
The company is headquartered in Bagsværd near Copenhagen but has operations across 37 locations in 19 countries with a total of 6,500 employees worldwide.
[94]
Ownership - Novo Nordisk Fonden
Oct 16, 2024 · Our investment activities as well as our ownership in the Novo Group companies are managed by our fully owned subsidiary Novo Holdings A/S.
[95]
Novonesis: A New Beginning For Novozymes And Christian Hansen
Mar 6, 2024 · Annual Results In fiscal 2023, Novozymes generated DKK 17,899 million in revenue and compared to DKK 17,553 million in fiscal 2022, the company ...Missing: size | Show results with:size
[96]
Legacy Novozymes delivers solid last full-year results
No readable text found in the HTML.<|separator|>
[97]
Novozymes: Merger with Chr. Hansen - VP Bank
After the closing of the deal the combined group will have annual revenues of EUR 3.5 billion (Novozymes EUR 2.3 billion), an Ebitda margin of 35% (Novozymes 34 ...Missing: announcement | Show results with:announcement
[98]
[PDF] Novozymes announces its 2025 strategy: Unlocking growth - Nasdaq
Sep 27, 2021 · We commit to clear targets until 2025 and we are looking further ahead with an ambition to double our sales by. 2030. In addition to the ...Missing: revenue | Show results with:revenue
[99]
Financial statement for the first nine months of 2000 - GlobeNewswire
Novozymes: Novozymes sales increased 13% to DKK 3,738 million, of which 8% is due to increase in currencies. Operating profit increased 24% to DKK 585 million.
[100]
What are Mission Vision & Core Values of Novozymes Company?
Oct 1, 2025 · This commitment is reflected in its R&D spending, which reached DKK 2.7 billion in 2023, demonstrating its dedication to scientific exploration ...Missing: percentage | Show results with:percentage
[101]
[PDF] 2024 organic pro forma sales growth of 8%, with pro ... - Novonesis
Feb 26, 2025 · Novonesis' 2024 organic pro forma sales growth was 8%, with a 36.1% adjusted EBITDA margin. 2025 outlook is 5-8% organic sales growth and 37-38 ...
[102]
[PDF] Interim report H1 2025 - Novonesis
Aug 21, 2025 · Administrative costs increased by 5% in H1 2025, equal to 5.4% of sales, compared to 5.6% (IFRS: 5.4%) in H1 last year. For Q2, this was 5.5% ...